论文部分内容阅读
目的探讨依达拉奉治疗急性脑梗死(ACI)的临床疗效。方法回顾性分析某院收治的ACI患者,经尿激酶治疗的ACI患者作为对照组,经尿激酶和依达拉奉治疗的ACI患者作为治疗组,比较两组的临床疗效、ESS和ADL评分。结果治疗组和对照组的总有效率为96.5%和88.6%,治疗组的总有效率明显高于对照组,差异具有统计学意义,且治疗组的ESS和ADL评分明显高于对照组。结论尿激酶溶栓治疗联合依达拉奉是治疗ACI的有效方法,值得临床进一步推广应用。
Objective To investigate the clinical efficacy of edaravone in the treatment of acute cerebral infarction (ACI). Methods The ACI patients admitted to a hospital, ACI patients treated with urokinase as control group and ACI patients treated with urokinase and edaravone as the treatment group were retrospectively analyzed. The clinical efficacy, ESS and ADL scores were compared between the two groups. Results The total effective rates of the treatment group and the control group were 96.5% and 88.6%, respectively. The total effective rate of the treatment group was significantly higher than that of the control group. The difference was statistically significant. The ESS and ADL scores of the treatment group were significantly higher than those of the control group. Conclusion Urokinase thrombolytic therapy combined with edaravone is an effective method for the treatment of ACI and is worth further clinical application.